|
|
|
GSK Dividend History & Description — GSK plc
GSK is a biopharma company. Co. is engaged in making vaccines and specialty medicines to prevent and treat disease. Co.'s research and development focuses on the science of the immune system, human genetics and advanced technologies primarily in the following four therapeutic areas: infectious diseases, HIV, oncology and immunology/respiratory. Co.'s two reportable segments include: Commercial Operations and Total research and development. When considering the GSK plc stock dividend history, we have taken known splits into account, such that the GSK dividend history is presented on a split-adjusted ("apples to apples") basis. GSK plc dividend history is presented both in graphical/chart form, and as a GSK dividend history data table along the right-hand column.
Name: |
GSK plc |
Website: |
www.gsk.com |
Sector: |
Drugs & Pharmaceuticals |
Number of ETFs Holding GSK: |
12 (see which ones) |
Total Market Value Held by ETFs: |
$214,670,215 |
Total Market Capitalization: |
$125,834,000,000 |
% of Market Cap. Held by ETFs: |
0.17% |
|
GSK Stock Dividend HistoryThe GSK dividend history graphic shown above is presented after taking into consideration any known stock split occurrences, in order to present the most directly comparable GSK historical dividend comparison possible. Historical dividends, when charted graphically, can reveal the long-term variability and/or growth within the GSK dividend history record. Also see the GSK stock dividend history data table along the right-hand column below.
|
|
|
|
Quotes delayed 20 minutes
|
Hold (2.11 out of 4)
3rd percentile
|
PARTNER NEWS:Fri, May 3, 3:08 AM, Zacks
The Zacks Analyst Blog Highlights Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine are included in this Analyst Blog.
Thu, May 2, 8:02 AM, Zacks
Biotech Stock Roundup: GILD's GSK' Q1 Earnings, DCPH Soars on Acquisition News & More Deciphera Pharmaceuticals, Inc. (DCPH) and GSK are in focus on acquisition news and Q1 earnings, respectively.
|
|